Blair William & Co. IL Cuts Position in Stryker Corporation $SYK

Blair William & Co. IL lowered its holdings in Stryker Corporation (NYSE:SYK) by 0.5% in the third quarter, Holdings Channel.com reports. The fund owned 919,505 shares of the medical technology company’s stock after selling 4,752 shares during the quarter. Stryker makes up 0.9% of Blair William & Co. IL’s investment portfolio, making the stock its 21st largest position. Blair William & Co. IL’s holdings in Stryker were worth $339,913,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in SYK. Brighton Jones LLC lifted its stake in shares of Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. purchased a new stake in Stryker during the second quarter worth $205,000. First Horizon Advisors Inc. boosted its position in shares of Stryker by 17.7% in the 2nd quarter. First Horizon Advisors Inc. now owns 2,894 shares of the medical technology company’s stock worth $1,146,000 after buying an additional 435 shares in the last quarter. Souders Financial Advisors acquired a new position in Stryker during the second quarter worth about $212,000. Finally, Soltis Investment Advisors LLC grew its position in shares of Stryker by 26.1% in the second quarter. Soltis Investment Advisors LLC now owns 1,796 shares of the medical technology company’s stock valued at $710,000 after purchasing an additional 372 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. This trade represents a 9.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.90% of the stock is owned by corporate insiders.

Stryker Stock Performance

Shares of SYK stock opened at $364.11 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The firm has a market capitalization of $139.34 billion, a price-to-earnings ratio of 43.35, a price-to-earnings-growth ratio of 2.16 and a beta of 0.85. Stryker Corporation has a one year low of $329.16 and a one year high of $404.87. The company has a 50 day moving average price of $365.45 and a 200 day moving average price of $369.14.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. The company had revenue of $7.17 billion for the quarter, compared to analyst estimates of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. Stryker’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the business earned $4.01 EPS. Sell-side analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s payout ratio is 41.90%.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Evercore set a $390.00 price objective on Stryker in a research report on Monday, January 5th. BTIG Research boosted their price target on Stryker from $410.00 to $412.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Citigroup restated a “market outperform” rating on shares of Stryker in a research report on Friday, January 30th. TD Cowen cut shares of Stryker from a “buy” rating to a “hold” rating and set a $387.00 target price for the company. in a research note on Monday, January 26th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $465.00 target price on shares of Stryker in a research note on Wednesday. Fourteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $428.61.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.